CONSTITUENT REPORT
cis-Thujone
cis-Thujone is the cis-configured thujone isomer usually mapped in modern databases to alpha-thujone, a monoterpene ketone found in mugwort, sage, wormwood, and related Artemisia materials. The public evidence base is driven mainly by occurrence data, neuropharmacology, and toxicology rather than by wellness-style studies. For AromaForge, cis-thujone is best treated as a safety-relevant chemotype constituent with experimental central-nervous-system activity and clear exposure-control implications.
Chemical identity and composition
PubChem and ChemEO both associate cis-thujone naming with the alpha-thujone stereochemical family, while NIST's non-isomer-specific thujone page shows how public registries can blur the boundary between the isomer pair and shared skeleton entries. In the local archive, Artemisia vulgaris mugwort records cite cis-thujone at 0-12.9% in North Lithuania oils. Because public databases expose both isomer-specific and pooled thujone records, identity language should stay explicit about whether a source means cis/alpha-thujone alone or total thujones.
Aroma and practical use
- Use the recorded sharp, herbal, camphoraceous, sage-like, herbaceous, medicinal descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Compare the recorded goal signals with the intended purpose, while keeping model assumptions separate from observed study outcomes.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A Brain Research chick study found that centrally administered alpha- and beta-thujone both produced anxiogenic-like behavioral effects at 78 nmol, while only alpha-thujone reversed stress-induced GABAA receptor recruitment in that model.
A Brain Research chick study found that centrally administered alpha- and beta-thujone both produced anxiogenic-like behavioral effects at 78 nmol, while only alpha-thujone reversed stress-induced GABAA receptor recruitment in that model.
This experimental finding does not establish benefit, dose or safety in people using this blend.
The North Lithuania mugwort survey reported cis-thujone as a second dominant constituent in one Artemisia vulgaris oil, with a reported range of 0-12.9% across the seven analyzed samples.
The North Lithuania mugwort survey reported cis-thujone as a second dominant constituent in one Artemisia vulgaris oil, with a reported range of 0-12.9% across the seven analyzed samples.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
The National Toxicology Program's thujone report and related toxicology reviews reinforce that thujone-class safety concerns focus on neurotoxicity and seizure-like findings, though those materials usually evaluate alpha-thujone or mixed alpha,beta-thujone rather than consumer-style aromatherapy use.
The National Toxicology Program's thujone report and related toxicology reviews reinforce that thujone-class safety concerns focus on neurotoxicity and seizure-like findings, though those materials usually evaluate alpha-thujone or mixed alpha,beta-thujone rather than consumer-style aromatherapy use.
This experimental finding does not establish benefit, dose or safety in people using this blend.
How it contributes to goal calculations
Model markers guide the formulation score. They are separate from the source findings above.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedThe clearest public safety signal is dose-related neurotoxicity, including excitation and convulsant risk, especially in thujone-rich materials.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
EMA's public statement on thujone-containing herbal medicinal products supports exposure control and caution for sensitive populations rather than broad benefit framing.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
Public records use both isomer-specific and pooled thujone identifiers, so constituent-level safety summaries should state clearly whether they refer to cis/alpha-thujone alone or total thujones.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
beta-ThujoneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
animal · effect
No source citation attached.
Read beta-Thujone report →beta-ThujoneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
toxicology · effect
No source citation attached.
Read beta-Thujone report →How the effects were investigated
gaba a modulation
Thujone-class neuroactivity is best supported through interaction with GABAA-related signaling, with cis-thujone generally represented in the literature as the alpha-thujone isomer.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- Accessible databases map cis-thujone inconsistently across alpha-thujone, isothujone, and broader thujone entries, so stereochemical normalization may still need a later curation pass.
- Human dose-response data specific to isolated cis-thujone were not located in the reviewed public sources.
- Most safety and toxicology literature evaluates alpha-thujone or mixed alpha,beta-thujone rather than cis-thujone as a separately used commercial constituent.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.